201 related articles for article (PubMed ID: 35413980)
1. Measuring treatment attrition at various stages of engagement in Opioid Agonist Treatment in Ontario Canada using a cascade of care framework.
Tahsin F; Morin KA; Vojtesek F; Marsh DC
BMC Health Serv Res; 2022 Apr; 22(1):490. PubMed ID: 35413980
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study.
Paul LA; Bayoumi AM; Chen C; Kocovska E; Smith BT; Raboud JM; Gomes T; Kendall C; Rosella LC; Bitonti-Bengert L; Rush B; Yu M; Spithoff S; Crichlow F; Wright A; Watford J; Besharah J; Munro C; Taha S; Nosyk B; Strike C; Manson H; Kahan M; Leece P
Addiction; 2023 Apr; 118(4):686-697. PubMed ID: 36401610
[TBL] [Abstract][Full Text] [Related]
3. The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada.
Piske M; Zhou H; Min JE; Hongdilokkul N; Pearce LA; Homayra F; Socias ME; McGowan G; Nosyk B
Addiction; 2020 Aug; 115(8):1482-1493. PubMed ID: 31899565
[TBL] [Abstract][Full Text] [Related]
4. Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006-2016.
Socías ME; Wood E; Kerr T; Nolan S; Hayashi K; Nosova E; Montaner J; Milloy MJ
Drug Alcohol Depend; 2018 Aug; 189():90-95. PubMed ID: 29894910
[TBL] [Abstract][Full Text] [Related]
5. Negative Impact of Amphetamine-Type Stimulant Use on Opioid Agonist Treatment Retention in Ontario, Canada.
Morin KA; Vojtesek F; Acharya S; Marsh DC
Front Psychiatry; 2021; 12():782066. PubMed ID: 34987430
[No Abstract] [Full Text] [Related]
6. Canadian Addiction Treatment Centre (CATC) opioid agonist treatment cohort in Ontario, Canada.
Morin KA; Tatangelo M; Marsh D
BMJ Open; 2024 Feb; 14(2):e080790. PubMed ID: 38401902
[TBL] [Abstract][Full Text] [Related]
7. The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting.
Eibl JK; Gauthier G; Pellegrini D; Daiter J; Varenbut M; Hogenbirk JC; Marsh DC
Drug Alcohol Depend; 2017 Jul; 176():133-138. PubMed ID: 28535455
[TBL] [Abstract][Full Text] [Related]
8. Opioid agonist therapy during residential treatment of opioid use disorder: Cohort study on access and outcomes.
Spithoff S; Meaney C; Urbanoski K; Harrington K; Que B; Kahan M; Leece P; Shehadeh V; Sullivan F
Can Fam Physician; 2019 Oct; 65(10):e443-e452. PubMed ID: 31604755
[TBL] [Abstract][Full Text] [Related]
9. Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.
Russell C; Nafeh F; Pang M; MacDonald SF; Derkzen D; Rehm J; Fischer B
BMC Public Health; 2022 Mar; 22(1):436. PubMed ID: 35246083
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the association between urine drug screening frequency and retention in opioid agonist treatment in Ontario, Canada: a retrospective cohort study.
Morin KA; Dabous JR; Vojtesek F; Marsh D
BMJ Open; 2022 Oct; 12(10):e060857. PubMed ID: 36223960
[TBL] [Abstract][Full Text] [Related]
11. Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada.
Russell C; Pang M; Nafeh F; Farrell Macdonald S; Derkzen D; Rehm J; Fischer B
Int J Qual Stud Health Well-being; 2022 Dec; 17(1):2094111. PubMed ID: 35787743
[TBL] [Abstract][Full Text] [Related]
12. The impact of cocaine use in patients enrolled in opioid agonist therapy in Ontario, Canada.
Franklyn AM; Eibl JK; Gauthier GJ; Pellegrini D; Lightfoot NE; Marsh DC
Int J Drug Policy; 2017 Oct; 48():1-8. PubMed ID: 28666202
[TBL] [Abstract][Full Text] [Related]
13. A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data.
Morin KA; Eibl JK; Gauthier G; Rush B; Mushquash C; Lightfoot NE; Marsh DC
Harm Reduct J; 2020 Jul; 17(1):51. PubMed ID: 32703310
[TBL] [Abstract][Full Text] [Related]
14. The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study.
Gisev N; Bharat C; Larney S; Dobbins T; Weatherburn D; Hickman M; Farrell M; Degenhardt L
Lancet Public Health; 2019 Jul; 4(7):e334-e342. PubMed ID: 31201133
[TBL] [Abstract][Full Text] [Related]
15. Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions.
Bouck Z; Scheim AI; Gomes T; Ling V; Caudarella A; Werb D
Int J Drug Policy; 2022 Jun; 104():103680. PubMed ID: 35447476
[TBL] [Abstract][Full Text] [Related]
16. Evidence of increased Fentanyl use during the COVID-19 pandemic among opioid agonist treatment patients in Ontario, Canada.
Morin KA; Acharya S; Eibl JK; Marsh DC
Int J Drug Policy; 2021 Apr; 90():103088. PubMed ID: 33385974
[TBL] [Abstract][Full Text] [Related]
17. The Future of Opioid Agonist Therapies in Ukraine: A Qualitative Assessment of Multilevel Barriers and Ways Forward to Promote Retention in Treatment.
Bojko MJ; Mazhnaya A; Marcus R; Makarenko I; Islam Z; Filippovych S; Dvoriak S; Altice FL
J Subst Abuse Treat; 2016 Jul; 66():37-47. PubMed ID: 27211995
[TBL] [Abstract][Full Text] [Related]
18. Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients' and prescribers' experiences with changes in unsupervised dosing.
Corace K; Suschinsky K; Wyman J; Leece P; Cragg S; Konefal S; Pana P; Barrass S; Porath A; Hutton B
Int J Drug Policy; 2022 Apr; 102():103573. PubMed ID: 35123246
[TBL] [Abstract][Full Text] [Related]
19. Initiation of opioid agonist treatment and subsequent substance use and other patterns among adolescents and young adults in Vancouver, Canada.
Pilarinos A; Fast D; Nosova E; Kwa Y; Joe R; Buxton JA; DeBeck K
Drug Alcohol Depend; 2022 Jun; 235():109441. PubMed ID: 35427979
[TBL] [Abstract][Full Text] [Related]
20. Opioid agonist therapy engagement and crystal methamphetamine use: The impact of unregulated opioid use in Vancouver, Canada.
Cui Z; Bach P; Ti L; Hayashi K; Morgan J; Milloy MJ; Kerr T
Int J Drug Policy; 2022 Dec; 110():103879. PubMed ID: 36265327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
